 The results of pre-clinical in-vivo research studies suggested that Clearminds drug candidate MEAI may be effective in the treatment of substance addiction without interrupting the natural reward process Tel Aviv, Israel Vancouver, Canada, Jan. 17, 2023 GLOBE NEWSWIRE Clearmind Medicine Inc. Nasdaq, CSE: CMND, FSE: CWY Clearmind or the Company, a biotech company... The post Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study f... 